alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 3,126–3,150 of 27,380 studies, newest first · page 126 of 1096.

September 2025 25

  1. 2025-09-24

    CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling

    ✓ Peer-reviewed Laboratory science Nature Communications

    Key finding: We conclude that communication between CD8 + T cells and the nervous system is altered in AD, paving the way for therapies targeting T cell-dependent neurotoxic inflammation.

    Full summary, score breakdown and related studies → Original source

  2. 2025-09-24

    Kisunla (donanemab) — EU Marketing Authorization (EPAR), following CHMP re-examination

    ⚠ Regulatory decision — not a study Treatments European Medicines Agency

    Key finding: Initial CHMP negative opinion (March 2025) reversed to a positive opinion after re-examination (July 24, 2025); EU authorization granted September 24, 2025 +2 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2025-09-23

    P2RX7 modulates the function of human microglia-like cells and mediates the association of IL18 with Alzheimer's disease traits

    ✓ Peer-reviewed Inflammation and the immune system Neurobiology of Disease

    Key finding: Our results show that ATP-stimulation of MDMi triggers upregulation of IL1β and IL18 expression, which is blocked with the A740003 P2RX7 antagonist. +3 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2025-09-23

    Associations of plasma p‐tau231 with serial position recall performance in free‐of‐dementia individuals

    ✓ Peer-reviewed Cognitive tests and assessment Journal of Neuropsychology

    Key finding: Cognitive assessment and analysis of plasma biomarkers are lower-cost options for the early assessment of Alzheimer's disease (AD).

    Full summary, score breakdown and related studies → Original source

  5. 2025-09-23

    Handwriting in Mild Cognitive Impairment: Reliability Assessment and Machine Learning–Based Screening

    ✓ Peer-reviewed Digital health tools JMIR Aging

    Key finding: The presented results suggest the suitability of ecological handwriting analysis for the all-around monitoring of MCI, from early screening to disease progression evaluation. +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2025-09-23

    Sensitivity and specificity of the Montreal cognitive assessment using U.S. National alzheimer coordinating centre uniform data set: a retrospective analysis of 16,309 participants

    ✓ Peer-reviewed Getting a diagnosis BMC Neurology

    Key finding: This study utilized an initial dataset of 188,700 participant records from NACC. +4 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2025-09-23

    Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages

    ✓ Peer-reviewed Biomarkers Neurology

    Key finding: Stage-specific tau-PET region-of-interest selection reduced required sample sizes by 30%-93% for detecting hypothetical disease-modifying drug effects. +3 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2025-09-22

    From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease

    ✓ Peer-reviewed Treatments Central nervous system agents in medicinal chemistry

    Key finding: While recent clinical advances, including monoclonal antibodies like lecanemab and donanemab (early stage), show promise in slowing cognitive decline by targeting amyloid-beta pathology, their use is associated with risks such as amyloid-related imaging abnormalities (ARIA).

    Full summary, score breakdown and related studies → Original source

  9. 2025-09-22

    Biomarkers for Alzheimer's disease are upregulated in patients with diabetic retinopathy

    ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

    Key finding: All six biomarkers were significantly higher in plasma in participants with DR compared to those without DR [Aβ40 p = 0.002, Aβ42 p = 0.002, t-tau = 0.013, ptau181 p = 0.005, GFAP p = 0.010, and NfL p < 0.001]. +3 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2025-09-22

    Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer's disease

    ✓ Peer-reviewed Treatments Expert review of clinical pharmacology

    Key finding: However, these therapies are associated with amyloid-related imaging abnormalities (ARIA), particularly in individuals carrying the APOE ε4 allele, necessitating close monitoring and individualized risk assessment. +1 more finding

    Full summary, score breakdown and related studies → Original source

  11. 2025-09-22

    New landscape of the diagnosis of Alzheimer's disease

    ✓ Peer-reviewed Treatments Lancet (London, England)

    Key finding: Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. +4 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2025-09-22

    MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics

    ✓ Peer-reviewed Vascular contributions Annals of Neurology

    Key finding: MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non-Hispanic Black. +4 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2025-09-22

    Palliative care integration in psychiatric disorders: bibliometric analysis revealing five distinct research clusters

    ✓ Peer-reviewed End-of-life care BMJ Supportive & Palliative Care

    Key finding: The analysis reveals a significant acceleration in research activity after 2017. +4 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2025-09-22

    Free-Text Responses in a Nationally Representative Experimental Survey about End-of-Life Care Choices: ChatGPT-4o-Assisted Qualitative Analytical Study

    ✓ Peer-reviewed End-of-life care JMIR Aging

    Key finding: We identified several key themes: surrogates more often chose comfort care for care recipients with dementia, particularly at advanced stages. +4 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2025-09-22

    Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies

    ✓ Peer-reviewed Risk genes beyond APOE Experimental Neurology

    Key finding: Microglial interactions with Aβ likely influence the outcomes of Aβ-targeting therapies, and characterizing their dynamic states will inform the development of diagnostic tools and treatments relying on microglial activation to alleviate pathologies associated with neurodegenerative diseases. • TREM2, Axl, and Gal-3 increase with age and colocalize with amyloid plaques in mouse models of amyloid-beta pathology. • Different Aβ isoforms may drive the brain concentrations of inflammation proteins. • Type and length of treatment impact inflammation protein levels differently. • Extracellular TREM2, Axl, and galectin-3 are promising PET targets for monitoring Alzheimer-related microglial activation.

    Full summary, score breakdown and related studies → Original source

  16. 2025-09-22

    Aesthetic Experience in the Acceptance of Wearable Technology for People With Dementia: Critical Interpretive Synthesis

    ✓ Peer-reviewed Digital health tools JMIR Aging

    Key finding: A total of 63 studies were included in this study. +4 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2025-09-22

    Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease

    ✓ Peer-reviewed Down syndrome and Alzheimer's Annals of neurology

    Key finding: The patterns of FDG decline are distinct in these 2 genetically determined forms of AD.

    Full summary, score breakdown and related studies → Original source

  18. 2025-09-21

    Exploring the relationship between epilepsy and neurodegenerative diseases

    ✓ Peer-reviewed Down syndrome and Alzheimer's Romanian Journal of Neurology

    Key finding: A bidirectional relationship has been identified between dementia and epilepsy.

    Full summary, score breakdown and related studies → Original source

  19. 2025-09-20

    Generation of a recombinant GST-Tau antigen for indirect ELISA in evaluating Alzheimer’s disease vaccines

    ⚠ Preprint — not yet peer-reviewed Drug development bioRxiv

    Key finding: A robust method was developed to produce and optimize GST-Tau as a coating antigen for indirect ELISA.

    Scored 19 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  20. 2025-09-19

    Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results

    ✓ Peer-reviewed Prevention and risk Progress in lipid research

    Key finding: However, the results of clinical trials have been inconsistent and mixed, and this may be due to the considerable heterogeneity in trial designs, but also a lack of appreciation of methodological complications unique to omega-3 PUFA research.

    Full summary, score breakdown and related studies → Original source

  21. 2025-09-19

    Exploring the Feasibility of the LEAD Trial: Online Dyadic Dementia Care Planning for Early Alzheimer's and Other Dementias

    ✓ Peer-reviewed End-of-life care American Journal of Hospice and Palliative Medicine®

    Key finding: Our findings suggest the LEAD intervention is feasible and demonstrates initial efficacy in promoting dementia-focused ACP. +2 more findings

    Full summary, score breakdown and related studies → Original source

  22. 2025-09-19

    Investigating Potential Alzheimer's Disease Therapies through an Agent-Based Model of Impaired Microglia MetabolismModeling Impaired Microglia Metabolism

    ✓ Peer-reviewed Inflammation and the immune system Spora A Journal of Biomathematics

    Key finding: Our findings suggest that these interventions can reduce amyloid-β plaque accumulation and slow the blood brain barrier breakdown; however, they may also unintentionally lower brain pH, highlighting a trade-off that warrants further investigation.

    Full summary, score breakdown and related studies → Original source

  23. 2025-09-19

    Vascular Dementia: From Pathophysiology to Therapeutic Frontiers

    ✓ Peer-reviewed Lewy body dementia Journal of Clinical Medicine

    Key finding: Vascular dementia (VaD) represents the second-most common dementia type after Alzheimer's disease since it results from complications of cerebrovascular disease. +1 more finding

    Full summary, score breakdown and related studies → Original source

  24. 2025-09-19

    Hypertension, Diabetes and Depression as Modifiable Risk Factors for Dementia: A Common Data Model Approach in a Population-Based Cohort, with Study Protocol and Preliminary Results

    ✓ Peer-reviewed Risk factors Journal of Clinical Medicine

    Key finding: The final cohort comprised more than 3 million individuals, with a mean baseline age of 63–65 years and a female proportion of 52–55%. +3 more findings

    Full summary, score breakdown and related studies → Original source

  25. 2025-09-19

    Dementia Risk in People With Type 1 Diabetes and Associated Risk Factors: A Nationwide, Register-Based Cohort Study

    ✓ Peer-reviewed Risk factors Diabetes Care

    Key finding: After a median follow-up time of 14.3 (7.9-20.0) years, dementia was recorded in 530 (1.2%) individuals with type 1 diabetes and 1,867 (0.9%) age-, sex-, and county-matched control individuals (mean baseline age 33.0 [14.0] years). +3 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →